Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug dispositions

Drug Metabolism and Disposition

Volumn 42, Issue 3, 2014, Pages 448-458

  Lundquist, Patrik ^a,b,c   Englund, Gunilla ^a   Skogastierna, Cristine ^a   Lööf, Johan ^a   Johansson, Jenny ^a   Hoogstraate, Janet ^a   Afzelius, Lovisa ^a   Andersson, Tommy B ^b,d  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; ERYTHROMYCIN; FEXOFENADINE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN; DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DISPOSITION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRINSIC CLEARANCE; LIVER; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CRYOPRESERVATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLIC CLEARANCE RATE; METABOLISM; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; CRYOPRESERVATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEPATOCYTES; HUMANS; MALE; METABOLIC CLEARANCE RATE; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84907273240     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054528     Document Type: Article

References (54)

1. Benet LZ (2009) The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6:1631-1643.
2. Bissell DM and Guzelian PS (1980) Phenotypic stability of adult rat hepatocytes in primary monolayer culture. Ann N Y Acad Sci 349:85-98.
3. Bow DA, Perry JL, Miller DS, Pritchard JB, and Brouwer KL (2008) Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab Dispos 36:198-202.
4. Brown HS, Wilby AJ, Alder J, and Houston JB (2010) Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay. Drug Metab Dispos 38:2139-2146.
5. Chiba M, Ishii Y, and Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262-276.
6. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
7. Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi YA, Lai Y, Duckworth J, Fenner K, and Troutman MD, et al. (2012) Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem 57:441-448.
8. Floby E, Johansson J, Hoogstraate J, Hewitt NJ, Hill J, and Sohlenius-Sternbeck AK (2009) Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. Xenobiotica 39:656-662.
9. Gardiner P and Paine SW (2011) The impact of hepatic uptake on the pharmacokinetics of organic anions. Drug Metab Dispos 39:1930-1938.
10. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
11. Gray KA, Daugherty LC, Gordon SM, Seal RL, Wright MW, and Bruford EA (2013) Genenames.org: the HGNC resources in 2013. Nucleic Acids Res 41 (Database issue):D545-D552.
12. Groothuis GM, Hulstaert CE, Kalicharan D, and Hardonk MJ (1981) Plasma membrane specialization and intracellular polarity of freshly isolated rat hepatocytes. Eur J Cell Biol 26:43-51.
13. Hagenbuch B and Stieger B (2013) The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med 34:396-412.
14. Hegedüs T, Sessler T, Scott R, Thelin W, Bakos E, Váradi A, Szabó K, Homolya L, Milgram SL, and Sarkadi B (2003) C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins. Biochem Biophys Res Commun 302:454-461.
15. Ismair MG, Häusler S, Stuermer CA, Guyot C, Meier PJ, Roth J, and Stieger B (2009) ABC-transporters are localized in caveolin-1-positive and reggie-1-negative and reggie-2-negative microdomains of the canalicular membrane in rat hepatocytes. Hepatology 49:1673-1682.
16. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, Sugiyama Y, and Lai Y (2012) Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 9:3535-3542.
17. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
18. Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1-96.
19. Kurnik D, Wood AJ, and Wilkinson GR (2006) The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 80:228-234.
20. Lam JL and Benet LZ (2004) Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32:1311-1316.
21. Lam JL, Okochi H, Huang Y, and Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336-1344.
22. Li M, Yuan H, Li N, Song G, Zheng Y, Baratta M, Hua F, Thurston A, Wang J, and Lai Y (2008) Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. Eur J Pharm Sci 35:114-126.
23. Li N, Palandra J, Nemirovskiy OV, and Lai Y (2009a) LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species. Anal Chem 81:2251-2259.
24. Li N, Zhang Y, Hua F, and Lai Y (2009b) Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos 37:66-73.
25. Lundquist P, Lööf J, Sohlenius-Sternbeck A-K, Floby E, Johansson J, Bylund J, Hoogstraate J, Afzelius L, and Andersson TB (2014) The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. Drug Metab Dispos 42:469-480.
26. Matsson P, Pedersen JM, Norinder U, Bergström CA, and Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831.
27. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, and Sugiyama Y (2008) Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474-1483.
28. McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, and Riley RJ (2009) Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37:1259-1268.
29. Ménochet K, Kenworthy KE, Houston JB, and Galetin A (2012) Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos 40:1744-1756.
30. Morrissey KM, Wen CC, Johns SJ, Zhang L, Huang SM, and Giacomini KM (2012) The UCSF-FDA TransPortal: a public drug transporter database. Clin Pharmacol Ther 92:545-546.
31. Ortiz DF, Moseley J, Calderon G, Swift AL, Li S, and Arias IM (2004) Identification of HAX-1 as a protein that binds bile salt export protein and regulates its abundance in the apical membrane of Madin-Darby canine kidney cells. J Biol Chem 279:32761-32770.
32. Oude Elferink RP, Bakker CT, Roelofsen H, Middelkoop E, Ottenhoff R, Heijn M, and Jansen PL (1993) Accumulation of organic anion in intracellular vesicles of cultured rat hepatocytes is mediated by the canalicular multispecific organic anion transporter. Hepatology 17:434-444.
33. Ozawa N, Shimizu T, Morita R, Yokono Y, Ochiai T, Munesada K, Ohashi A, Aida Y, Hama Y, and Taki K, et al. (2004) Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm Res 21:2133-2134.
34. Petzinger E and Fückel D (1992) Evidence for a saturable, energy-dependent and carrier-mediated uptake of oral antidiabetics into rat hepatocytes. Eur J Pharmacol 213:381-391.
35. Pfeifer ND, Yang K, and Brouwer KL (2013) Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J Pharmacol Exp Ther 347:727-736.
36. Prasad B, Lai Y, Lin Y, and Unadkat JD (2013) Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci 102:787-793.
37. Rippin SJ, Hagenbuch B, Meier PJ, and Stieger B (2001) Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology 33:776-782.
38. Roberts MS, Magnusson BM, Burczynski FJ, and Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790.
39. Soars MG, McGinnity DF, Grime K, and Riley RJ (2007a) The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2-15.
40. Soars MG, Grime K, Sproston JL, Webborn PJ, and Riley RJ (2007b) Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859-865.
41. Soars MG, Webborn PJ, and Riley RJ (2009) Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol Pharm 6:1662-1677.
42. Sohlenius-Sternbeck AK, Jones C, Ferguson D, Middleton BJ, Projean D, Floby E, Bylund J, and Afzelius L (2012) Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42:841-853.
43. Sun H, Frassetto LA, Huang Y, and Benet LZ (2010) Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther 87:465-472.
44. Swift B, Tian X, and Brouwer KL (2009) Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. Pharm Res 26:1942-1951.
45. Tchaparian EH, Houghton JS, Uyeda C, Grillo MP, and Jin L (2011) Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos 39:2387-2394.
46. Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, and Brouwer KL (2008a) Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 36:911-915.
47. Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, and Brouwer KL (2008b) Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 36:61-64.
48. Tietz P, Jefferson J, Pagano R, and Larusso NF (2005) Membrane microdomains in hepatocytes: potential target areas for proteins involved in canalicular bile secretion. J Lipid Res 46:1426-1432.
49. Watanabe T, Maeda K, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009) Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab Dispos 37:1471-1479.
50. Yang X, Gandhi YA, Duignan DB, and Morris ME (2009) Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J 11:511-525.
51. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, and Brouwer KL (2006) Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J Pharmacol Exp Ther 319:1485-1491.
52. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, and Brouwer KL (2009) Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos 37:386-390.
53. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, and Nagar S, et al.; International Transporter Consortium (2013) ITC recommendations for transporter kinetic parameter estimation and translational modeling of transportmediated PK and DDIs in humans. Clin Pharmacol Ther 94:64-79.
54. Zhao P (2008) The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. Expert Opin Drug Metab Toxicol 4:151-164.